Sangha R - Search Results

1

Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M, Sawyer MB. Chu MP, et al. Among authors: sangha r. Clin Lung Cancer. 2015 Jan;16(1):33-9. doi: 10.1016/j.cllc.2014.07.005. Epub 2014 Aug 15. Clin Lung Cancer. 2015. PMID: 25246385

2

L-BLP25: a peptide vaccine strategy in non small cell lung cancer.

Sangha R, Butts C. Sangha R, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4. doi: 10.1158/1078-0432.CCR-07-0213. Clin Cancer Res. 2007. PMID: 17671159 Review.

3

Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.

Sangha R, Lara PN Jr, Mack P, Gandara DR. Sangha R, et al. Clin Lung Cancer. 2008;9 Suppl 3:S90-1. doi: 10.3816/CLC.2008.s.013. Clin Lung Cancer. 2008. PMID: 19419929 No abstract available.

4

Cooperative group research endeavors in small-cell lung cancer: current and future directions.

Sangha R, Lara PN Jr, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. Sangha R, et al. Clin Lung Cancer. 2009 Sep;10(5):322-30. doi: 10.3816/CLC.2009.n.044. Clin Lung Cancer. 2009. PMID: 19808190

5

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.

Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR. Mack PC, et al. Among authors: sangha r. J Thorac Oncol. 2009 Dec;4(12):1466-72. doi: 10.1097/JTO.0b013e3181bbf239. J Thorac Oncol. 2009. PMID: 19884861 Free article. Clinical Trial.

6

Adjuvant therapy in non-small cell lung cancer: current and future directions.

Sangha R, Price J, Butts CA. Sangha R, et al. Oncologist. 2010;15(8):862-72. doi: 10.1634/theoncologist.2009-0186. Epub 2010 Aug 3. Oncologist. 2010. PMID: 20682608 Free PMC article. Review.

7

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.

Sangha R, Davies AM, Lara PN Jr, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Sangha R, et al. J Thorac Oncol. 2011 Dec;6(12):2112-9. doi: 10.1097/JTO.0b013e31822ae061. J Thorac Oncol. 2011. PMID: 21892109 Free PMC article. Clinical Trial.

8

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.

Ho C, Davies AM, Sangha RS, Lau D, Lara P Jr, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Ho C, et al. Among authors: sangha rs. Invest New Drugs. 2013 Dec;31(6):1587-91. doi: 10.1007/s10637-013-0024-y. Epub 2013 Sep 8. Invest New Drugs. 2013. PMID: 24013936 Free PMC article. Clinical Trial.

9

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Ramalingam S, et al. Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19. Ann Oncol. 2013. PMID: 24050956 Free article. Clinical Trial.

10

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW. Chu QS, et al. Among authors: sangha r. Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19. Invest New Drugs. 2014. PMID: 25037863 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters